TGFBR1 and hypertrophic cardiomyopathy: ALK5 inhibitor SD-208 exhibits antifibrotic activity by reverting myofibroblasts to fibroblasts in hypertrophic cardiomyopathy and inhibiting small extracellular vesicle secretion